Skip to content

Evaluation of the effectiveness of three nonbiologic DMARDs [salazosulfapyridine(SSZ), bucillamine(BUC), methotrexate(MTX)] combination therapy for early RA

Evaluation of the effectiveness of three nonbiologic DMARDs [salazosulfapyridine(SSZ), bucillamine(BUC), methotrexate(MTX)] combination therapy for early RA - JANET(Japan Nonbiologic DMARDs effectiveness Trial)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003615
Enrollment
20
Registered
2010-05-14
Start date
2010-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RA(Rheumatoid Arthritis)

Interventions

Using 3 DMARDs(Salazosulfapyridine, Bucillamine, and Methotrexate) for 24 months

Sponsors

St Luke's International Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who fulfilled the ACR and EULAR classification criteria for RA within 6 months . (Onset less than 1 year )

Exclusion criteria

Exclusion criteria: The past and complications 1)Patients with rheumatic diseases other than Sjogren's syndrome 2)Patient who has allergy in sulfa drugs 3)Patient with complications, such as the clinically signficant heart, lungs,liver and kidney disease,and blood dyscrasia Medicine 4)Patient with the history(less than 3 months)of SSZ, BUC, and MTX use 5)Patient with the history of biological DMARDs use 6)Patient who received intra-articular steroid injection within 4 weeks before the enrollment 7)Patient treated with steroid medication(oral,intravenous,intramuscular, or rectal administration;PSL equivalent dose>5mg/day within four weeks, before the enrollment) Operation/Treatment 8)Patient had an operation for RA within 6 months, before the enrollment 9)Patients with one of the following treatment 1 Plasma exchange 2 Leukocyte depletion therapy 3 Joint puncture and drainage for evaluated joints Others 10)Age < 20 years old or > 80 years old 11)Prengnant or lactating patients, and patients who wish to become pregnant within three months after the enrollment. Patients who wish their partner's pregnancy by three months after the test period end which is a schedule during the test period 12)Patients whom the investigator considers to be unsuitable for the study

Design outcomes

Primary

MeasureTime frame
28- tender joint count (T28), 28- swollen joint count (S28), CRP,MMP-3,Rheumatoid ractor,Anti-CCP, antibody,ESR GH,VAS(mm), mHAQ

Secondary

MeasureTime frame
DAS28(ESR/CRP), Remmision achievement rate on DAS28, EULAR response rate, CDAI:Clinical Disease Activity Index, ACR 50 and 70 response rates, Hand and foot X-ray (using modified Total Sharp Score method), Bone density(Lumber spine or femoral neck)

Countries

Japan

Contacts

Public ContactMitsumasa Kishimoto

St Luke's International Hospital The Section of Allergy&Rheumatology

03(3541)5151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026